Critical Path Institute (C-Path) is pleased to announce the launch of the Type 1 Diabetes (T1D) Consortium. Funded by The Leona M. and Harry B. Helmsley Charitable Trust; Janssen Research & Development, LLC; JDRF International; and Sanofi, the T1D Consortium will work to qualify islet autoimmunity antibodies as prognostic biomarkers to be used in the development of therapies for the treatment, and ultimately the prevention, of T1D.

Additional independent studies presented at the 70^th Society of Surgical Oncology Annual Cancer Symposium confirm performance and clinical impact of test. 

Seven Arizona bioscience startup firms were competitively selected to participate in the 2017 Flinn Foundation Bioscience Entrepreneurship Program, which was established to foster entrepreneurship and help early-stage bioscience companies develop into successful and sustainable businesses in Arizona.